Alzheimer's Disease and Animal Models

描述(由申请人提供)：约翰霍普金斯大学阿尔茨海默病研究中心(ADRC)的总体目标是促进整个JHU和相关机构的研究界对阿尔茨海默病(AD)和相关疾病的研究。ADRC由四个核心组成：临床核心、数据管理和统计核心、神经病理学核心和教育核心。这些核心将共同努力，为JHU社区提供基础设施和资源，以便AD和相关疾病的临床和基础研究能够继续蓬勃发展和扩大。此外，还提出了三个项目。第一个项目涉及轻度认知障碍(MCI)受试者的执行功能障碍及其与随着时间的推移认知能力下降的关系。第二个项目涉及在内侧颞叶穿通通路的最早病理阶段出现的临床-病理-生化变化，这些人已经进行了尸检，并且要么是正常的，要么符合MCI的标准，要么患有轻度AD。第三个项目将检查神经病理学、神经化学和生物化学方面的突触病理发生在几个品系的行为特征转基因小鼠。将继续与其他ADC和相关研究机构的研究人员进行合作研究，包括多中心临床试验。与AD研究界其他研究人员的数据共享将继续通过定期提交给国家阿尔茨海默病协调中心(NACC)。

DESCRIPTION (provided by applicant): The overall goal of the Alzheimer's Disease Research Center (ADRC) at Johns Hopkins University (JHU) is to facilitate research in Alzheimer's disease (AD) and related disorders throughout the research community at JHU and associated institutions. The ADRC is comprised of four Cores: a Clinical Core , a Data Management and Statistics Core, a Neuropathology Core, and an Education Core. The cores will work together to provide the infrastructure and resources to the JHU community so that clinical and basic research in AD and related disorders can continue to flourish and expand. In addition, three projects are proposed. The first Project pertains to executive function impairments in subjects with Mild Cognitive Impairment (MCI) and their relation to progression of cognitive decline over time. The second Project pertains to the clinical-pathological-biochemical alterations present in the earliest stage of pathology in the perforant pathway of the medial temporal lobe among individuals who have come to autopsy, and are either normal, meet criteria for MCI, or have mild AD. The third Project will examine neuropathological, neurochemical, and biochemical aspects of synaptic pathology occurring in several lines of behaviorally-characterized transgenic mice. Cooperative studies with investigators at other ADCs and related research institutions will continue to be conducted, including multi-center clinical trials. Data sharing with other investigators in the AD research community will continue through regular submissions to the National Alzheimer Disease Coordinating Center (NACC).